Literature DB >> 24607955

Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling.

Veena Sangkhae1, Sebastian Jonas Saur2, Alexis Kaushansky3, Kenneth Kaushansky1, Ian Stuart Hitchcock4.   

Abstract

Thrombopoietin (TPO) is the primary regulator of platelet production, affecting cell survival, proliferation, and differentiation through binding to and stimulation of the cell surface receptor the cellular myeloproliferative leukemia virus oncogene (c-Mpl). Activating mutations in c-Mpl constitutively stimulate downstream signaling pathways, leading to aberrant hematopoiesis, and contribute to development of myeloproliferative neoplasms. Several studies have mapped the tyrosine residues within the cytoplasmic domain of c-Mpl that mediate these cellular signals; however, secondary signaling pathways are incompletely understood. In this study, we focused on c-Mpl tyrosine 591 (Y591). We found Y591 of wild-type c-Mpl to be phosphorylated in the presence of TPO. Additionally, eliminating Y591 phosphorylation by mutation to Phe resulted in decreased total receptor phosphorylation. Using a Src homology 2/phosphotyrosine-binding (SH2/PTB) domain binding microarray, we identified novel c-Mpl binding partners for phosphorylated Y591, including Src homology region 2 domain-containing phosphatase-1 (SHP-1), spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK). The functional significance of binding partners was determined through small interfering RNA treatment of Ba/F3-Mpl cells, confirming that the increase in pERK1/2 resulting from removal of Y591 may be mediated by spleen tyrosine kinase. These findings identify a novel negative regulatory pathway that controls TPO-mediated signaling, advancing our understanding of the mechanisms required for successful maintenance of hematopoietic stem cells and megakaryocyte development.
Copyright © 2014 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24607955      PMCID: PMC5802363          DOI: 10.1016/j.exphem.2014.02.007

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  35 in total

1.  Quantifying protein-protein interactions in high throughput using protein domain microarrays.

Authors:  Alexis Kaushansky; John E Allen; Andrew Gordus; Michael A Stiffler; Ethan S Karp; Bryan H Chang; Gavin MacBeath
Journal:  Nat Protoc       Date:  2010-04-01       Impact factor: 13.491

Review 2.  The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production.

Authors:  Kenneth Kaushansky; Jonathan G Drachman
Journal:  Oncogene       Date:  2002-05-13       Impact factor: 9.867

3.  Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes.

Authors:  Y Miyakawa; P Rojnuckarin; T Habib; K Kaushansky
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

Review 4.  Targeting oncogenic Ras signaling in hematologic malignancies.

Authors:  Ashley F Ward; Benjamin S Braun; Kevin M Shannon
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

5.  Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.

Authors:  Wei Tong; Harvey F Lodish
Journal:  J Exp Med       Date:  2004-08-30       Impact factor: 14.307

6.  The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl.

Authors:  J G Drachman; J D Griffin; K Kaushansky
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

7.  Involvement of prolonged ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line.

Authors:  I Matsumura; K Nakajima; H Wakao; S Hattori; K Hashimoto; H Sugahara; T Kato; H Miyazaki; T Hirano; Y Kanakura
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

8.  Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.

Authors:  Norihiko Kawamata; Seishi Ogawa; Go Yamamoto; Soren Lehmann; Ross L Levine; Yana Pikman; Yasuhito Nannya; Masashi Sanada; Carl W Miller; D Gary Gilliland; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2008-08-23       Impact factor: 3.084

9.  Interaction of tyrosine-based sorting signals with clathrin-associated proteins.

Authors:  H Ohno; J Stewart; M C Fournier; H Bosshart; I Rhee; S Miyatake; T Saito; A Gallusser; T Kirchhausen; J S Bonifacino
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

10.  Establishment and erythroid differentiation of a cytokine-dependent human leukemic cell line F-36: a parental line requiring granulocyte-macrophage colony-stimulating factor or interleukin-3, and a subline requiring erythropoietin.

Authors:  S Chiba; F Takaku; T Tange; K Shibuya; C Misawa; K Sasaki; K Miyagawa; Y Yazaki; H Hirai
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

View more
  8 in total

1.  Conditional CRISPR-mediated deletion of Lyn kinase enhances differentiation and function of iPSC-derived megakaryocytes.

Authors:  Alyssa J Moroi; Peter J Newman
Journal:  J Thromb Haemost       Date:  2021-10-17       Impact factor: 5.824

2.  Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis.

Authors:  Jiansong Huang; Xin Huang; Yang Li; Xia Li; Jinghan Wang; Fenglin Li; Xiao Yan; Huanping Wang; Yungui Wang; Xiangjie Lin; Jifang Tu; Daqiang He; Wenle Ye; Min Yang; Jie Jin
Journal:  Front Med       Date:  2021-11-18       Impact factor: 9.927

Review 3.  Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.

Authors:  Isabelle Plo; Christine Bellanné-Chantelot; Matthieu Mosca; Stefania Mazzi; Caroline Marty; William Vainchenker
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-12       Impact factor: 5.555

4.  PKC-epsilon deficiency alters progenitor cell populations in favor of megakaryopoiesis.

Authors:  John C Kostyak; Elisabetta Liverani; Satya P Kunapuli
Journal:  PLoS One       Date:  2017-08-04       Impact factor: 3.240

5.  Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.

Authors:  Miki Hashimoto; Hidehiro Itonaga; Yasuhito Nannya; Hirokazu Taniguchi; Yuichi Fukuda; Takafumi Furumoto; Machiko Fujioka; Sachie Kasai; Masataka Taguchi; Hiroaki Taniguchi; Shinya Sato; Yasushi Sawayama; Sunao Atogami; Keisuke Iwasaki; Tomoko Hata; Hiroshi Soda; Yukiyoshi Moriuchi; Koh Nakata; Seishi Ogawa; Yasushi Miyazaki
Journal:  Intern Med       Date:  2019-12-26       Impact factor: 1.271

6.  Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors.

Authors:  Lu Cui; Ignacio Moraga; Tristan Lerbs; Camille Van Neste; Stephan Wilmes; Naotaka Tsutsumi; Aaron Claudius Trotman-Grant; Milica Gakovic; Sarah Andrews; Jason Gotlib; Spyros Darmanis; Martin Enge; Stephen Quake; Ian S Hitchcock; Jacob Piehler; K Christopher Garcia; Gerlinde Wernig
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

Review 7.  The thrombopoietin receptor: revisiting the master regulator of platelet production.

Authors:  Ian S Hitchcock; Maximillian Hafer; Veena Sangkhae; Julie A Tucker
Journal:  Platelets       Date:  2021-06-07       Impact factor: 3.862

8.  Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms.

Authors:  Chunjie Yu; Qiong Yang; Yuhong Chen; Demin Wang; Ross Levine; John Crispino; Qiang Wen; Zan Huang
Journal:  Cell Biosci       Date:  2016-05-23       Impact factor: 7.133

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.